185 related articles for article (PubMed ID: 28145609)
21. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
22. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
[TBL] [Abstract][Full Text] [Related]
23. Impact of an optical coherence tomography guided approach in acute coronary syndromes: A propensity matched analysis from the international FORMIDABLE-CARDIOGROUP IV and USZ registry.
Iannaccone M; D'Ascenzo F; Frangieh AH; Niccoli G; Ugo F; Boccuzzi G; Bertaina M; Mancone M; Montefusco A; Amabile N; Sardella G; Motreff P; Toutouzas K; Colombo F; Garbo R; Biondi-Zoccai G; Tamburino C; Omedè P; Moretti C; D'amico M; Souteyrand G; Meieir P; Lüscher TF; Gaita F; Templin C
Catheter Cardiovasc Interv; 2017 Aug; 90(2):E46-E52. PubMed ID: 28029210
[TBL] [Abstract][Full Text] [Related]
24. Percutaneous coronary intervention for acute coronary syndrome due to graft failure: use of bare-metal and drug-eluting stents and subsequent long-term clinical outcome.
Harskamp RE; Kuijt WJ; Damman P; Beijk MA; Grundeken MJ; Woudstra P; Tijssen JG; de Winter RJ
Catheter Cardiovasc Interv; 2014 Feb; 83(2):203-9. PubMed ID: 22508617
[TBL] [Abstract][Full Text] [Related]
25. First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial.
Grundeken MJ; Wykrzykowska JJ; Ishibashi Y; Garg S; de Vries T; Garcia-Garcia HM; Onuma Y; de Winter RJ; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; Meier B; Jüni P; Yazdani A; Copt S; Windecker S; Serruys PW
Catheter Cardiovasc Interv; 2016 Jun; 87(7):E248-60. PubMed ID: 26649651
[TBL] [Abstract][Full Text] [Related]
26. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry.
Colombo A; Chandrasekhar J; Aquino M; Ong TK; Sartori S; Baber U; Lee M; Iniguez A; Hajek P; Borisov B; Atzev B; Den Heijer P; Coufal Z; Hudec M; Mates M; Snyder C; Moalem K; Morrell D; Elmore F; Rowland S; Mehran R;
Int J Cardiol; 2019 May; 283():67-72. PubMed ID: 30826192
[TBL] [Abstract][Full Text] [Related]
28. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
[TBL] [Abstract][Full Text] [Related]
29. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial.
Sabaté M; Brugaletta S; Cequier A; Iñiguez A; Serra A; Hernádez-Antolín R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vázquez N; Backx B; Serruys PW
JACC Cardiovasc Interv; 2014 Jan; 7(1):64-71. PubMed ID: 24332423
[TBL] [Abstract][Full Text] [Related]
30. Comparison of two biodegradable-polymer-based sirolimus-eluting stents with varying elution and absorption kinetics in patients with acute myocardial infarction: A subgroup analysis of the PANDA III trial.
Guan C; Xu B; Qiao S; Qin L; Li Y; Li Z; Guo Y; Sun Z; Song L; Gao R;
Catheter Cardiovasc Interv; 2017 Mar; 89(S1):520-527. PubMed ID: 28109057
[TBL] [Abstract][Full Text] [Related]
31. Long-term clinical outcome after implantation of the self-expandable STENTYS stent in a large, multicenter cohort.
Gaede L; Liebetrau C; Dörr O; Blumenstein J; Elsässer A; Hamm CW; Möllmann H; Schlundt C; Nef HM; Achenbach S
Coron Artery Dis; 2017 Nov; 28(7):588-596. PubMed ID: 28704242
[TBL] [Abstract][Full Text] [Related]
32. One year clinical outcomes in patients with insulin-treated diabetes mellitus and non-insulin-treated diabetes mellitus compared to non-diabetics after deployment of the bio-engineered COMBO stent.
Kalkman DN; Woudstra P; den Heijer P; Menown IB; Erglis A; Suryapranata H; Arkenbout KE; Iñiguez A; van 't Hof AW; Muller P; Tijssen JG; de Winter RJ
Int J Cardiol; 2017 Jan; 226():60-64. PubMed ID: 27788391
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes after percutaneous coronary intervention with the COMBO stent versus Resolute Integrity and PROMUS Element stents: a propensity-matched analysis.
Kalkman DN; Kok MM; van der Heijden LC; Woudstra P; Beijk MAM; Tijssen JGP; von Birgelen C; de Winter RJ
EuroIntervention; 2017 Nov; 13(10):1202-1209. PubMed ID: 28870878
[TBL] [Abstract][Full Text] [Related]
34. Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations.
Magalhaes MA; Minha S; Chen F; Torguson R; Omar AF; Loh JP; Escarcega RO; Lipinski MJ; Baker NC; Kitabata H; Ota H; Suddath WO; Satler LF; Pichard AD; Waksman R
Circ Cardiovasc Interv; 2014 Dec; 7(6):768-76. PubMed ID: 25466551
[TBL] [Abstract][Full Text] [Related]
35. Outcomes after revascularisation with everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes and stable angina pectoris: a substudy of the SORT OUT IV trial.
Antonsen L; Thayssen P; Hansen HS; Maeng M; Tilsted HH; Bøtker HE; Ravkilde J; Madsen M; Sørensen HT; Thuesen L; Lassen JF; Jensen LO
EuroIntervention; 2014 Jun; 10(2):212-23. PubMed ID: 23838425
[TBL] [Abstract][Full Text] [Related]
36. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Camaro C; Damen SA; Brouwer MA; Kedhi E; Lee SW; Verdoia M; Barbieri L; Rognoni A; van T Hof AW; Ligtenberg E; de Boer MJ; Suryapranata H; De Luca G
Am Heart J; 2016 Aug; 178():37-44. PubMed ID: 27502850
[TBL] [Abstract][Full Text] [Related]
37. Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent.
Jakobsen L; Christiansen EH; Freeman P; Kahlert J; Veien K; Maeng M; Raungaard B; Ellert J; Kristensen SD; Christensen MK; Terkelsen CJ; Thim T; Eftekhari A; Jensen RV; Støttrup NB; Junker A; Hansen HS; Jensen LO
Catheter Cardiovasc Interv; 2023 Jan; 101(1):13-21. PubMed ID: 36378691
[TBL] [Abstract][Full Text] [Related]
38. Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis).
Waksman R; Kirtane AJ; Torguson R; Cohen DJ; Ryan T; Räber L; Applegate R; Waxman S; Gordon P; Kaneshige K; Leon MB;
JACC Cardiovasc Interv; 2014 Oct; 7(10):1093-102. PubMed ID: 25240540
[TBL] [Abstract][Full Text] [Related]
39. Outcomes following implantation of the Biolimus A9-eluting BioMatrix coronary stent: Primary analysis of the e-BioMatrix registry.
Urban P; Valdés M; Menown I; Eberli F; Alhaddad I; Hildick-Smith D; Iosseliani D; Roffi M; Oldroyd K; Kalloudi E; Eerdmans P; Berland J; Kleber FX;
Catheter Cardiovasc Interv; 2015 Dec; 86(7):1151-60. PubMed ID: 25683225
[TBL] [Abstract][Full Text] [Related]
40. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
Wimmer NJ; Dufour AB; Cho K; Gagnon DR; Quach L; Ly S; Do JM; Ostrowski S; Michael Gaziano J; Faxon DP; Kinlay S
Catheter Cardiovasc Interv; 2017 Jun; 89(7):1176-1184. PubMed ID: 27860195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
